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developmental pressure to delete or tolerize such T cells.
Overexpressed protein antigens associated with tumorigenicity
currently being targeted include the WT1 (Wilms’ tumor) gene in
leukemias and various solid tumors (Yamagami et al., 1996), and
HER-2/neu in breast and ovarian cancer (van de Vijver et al.,
1987). Aberrant expression in tumors of proteins found only in
normal tissues perceived as immune-privileged provides nearly
unique potential target antigens. The prototypes are cancer-
testis antigens, such as NY-ESO-1, which have unknown func-
tions but are expressed by transformed cells such as ovarian
cancer and melanoma and otherwise are detected only in nor-
mal germ cells (Chen et al., 1997). Alternatively, tumor antigens
might be selectively targeted if their expression is limited to nor-
mal tissues in which the consequences of autoimmune injury
would be acceptable, such as with PSA in prostate cancer and
normal prostatic tissue (Kuriyama et al., 1982) and MART-1 in
melanoma and normal melanocytes (Kawakami et al., 1994).
However, the risk of evasion would likely be greater with such
antigens, as demonstrated by the selective outgrowth of antigen-
loss mutants following immunotherapy of melanoma (Thurner et
al., 1999;Yee et al., 2002).
Methods for identifying tumor-specific or tumor-associated
antigens that might be targeted continue to improve with techno-
logical advances. One approach uses tumor-reactive T cells iso-
lated from the blood or tumor tissue (i.e., tumor-infiltrating
lymphocytes or TIL) of cancer patients to screen autologous tar-
get cells transfected with genes from a tumor-derived cDNA
expression library (Boon et al., 1994; Kawakami et al., 1994).
However, this strategy requires the prior isolation of tumor-reac-
tive T cells, and the antigens identified, while a priori immuno-
genic, may not be ideal targets. Another approach, SEREX, uses
antisera from cancer patients to screen tumor-derived expression
libraries for antigens that have induced antibody responses, on
the presumption that this might be associated with T cell respons-
es (Pfreundschuh, 2000). More than 1500 immunogenic tumor
proteins have been identified by this method, but the difficult
process of determining which of these antigens can actually elicit
CD8+ and/or CD4+ T cell responses remains.Whereas such tech-
niques screen for immunogenic proteins to identify candidate
tumor targets, an alternate strategy utilizes gene expression pro-
files—for example with microarrays or differential displays—to
screen tumor transcriptomes to identify candidate genes that are
selectively overexpressed in malignant versus normal cell types,
many of which can be identified as prooncogenic. The most suit-
able proteins can then be screened for immunogenicity.
Targeted destruction of malignancies by enhancing T cell
responses is an attractive modality for therapy because it poten-
tially allows for exquisite specificity and potent activity in the
elimination of target cells while avoiding toxicities associated
with many other standard approaches. However, therapeutic
vaccination of cancer patients has been difficult, due in part to
the immunocompromised status of patients and immune toler-
ance mechanisms that result in the deletion or anergy of self-
reactive T cells. Adoptive immunotherapy with large numbers of
ex vivo expanded effector T cells can overcome many of the
regulatory mechanisms that prevent the in vivo generation of
effective responses, and provides an opportunity to control the
magnitude, function, specificity, and target avidity of the antitu-
mor response. Adoptive therapy can also be used to rapidly
determine if potential antigens are valid therapeutic targets and
to define the goals that must be achieved for an effective vac-
cine. Moreover, T cells can be genetically modified prior to
administration to instill effector functions and specificities that
may not be normally present. This primer discusses the critical
steps and strategies being examined for the generation and
effective deployment of effector T cells in the treatment of
human cancer (Figure 1).
Target selection
There are several criteria that an optimal tumor antigen would
possess. Ideally, the target antigen would be expressed in the
malignant but not the normal cell type. Also, the target antigen
should be required by the tumor cells for growth or survival. This
would minimize the risk of evading the transferred T cells, either
by mutation or loss of expression of the antigen. Potential targets
in this category include epitopes from the BCR/ABL transloca-
tion in CML (Groffen et al., 1984), defined p21/ras mutations
found in multiple malignancies (Bos, 1988), and oncogenic viral
proteins such as HPV proteins in cervical cancer (zur Hausen,
1999) and EBV proteins in Hodgkin’s disease and nasopharyn-
geal carcinoma (Niedobitek et al., 2001). However, most candi-
date antigens will not fulfill these criteria, but rather will represent
nonmutated proteins that are overexpressed or aberrantly
expressed by the tumor. Again, proteins important for maintain-
ing the malignant phenotype should preferably be chosen.
Quantitatively higher expression of such proteins in malignant
cells compared to normal tissues may make it possible to isolate
effector cells with T cell receptor (TCR) affinities that recognize
and eliminate tumors while ignoring the low levels of antigen
expressed by normal tissues, since there should have been little
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In vitro generation of effector cells
The next step essential for adoptive immunotherapy is the gen-
eration of effector cells. Elucidation of the roles played by cellu-
lar and molecular factors in the development of in vivo immune
responses has led to improvements in the methods used to pro-
duce effector cells in vitro. The generation of CTL effectors ex
vivo may uncover responses not evident in the potentially
inhibitory in vivo environment. High-avidity CTL reactive with
tumor antigens that have escaped thymic deletion might still be
rendered nonresponsive (anergized) in the periphery by expres-
sion of the antigen in normal adult tissues or in the growing
tumor (Lee et al., 1999; Ohlen et al., 2002). Such T cells would
not likely respond to in vivo immunization with tumor or peptide-
based vaccines, but might respond in vitro in the absence of
negative effects from regulatory T cells or inhibitory signals like
CTLA-4 (Sutmuller et al., 2001).
The generation of T cells for tumor therapy has generally
involved the isolation and expansion of tumor-reactive CTL from
patients. A method used in several clinical trials utilizes T cell
lines derived from the in vitro culture of cells infiltrating tumor
tissue in extremely high concentrations of IL-2 without stimula-
tion with a selected target antigen (Dudley et al., 2002b). While
a significant amount of clinical data have been generated with
such TILs, polyclonal cells generated under such nonphysiolog-
ic conditions may have functional deficiencies limiting efficacy,
and the inability to adequately characterize the effector popula-
tion impedes rational improvement of this methodology.
Generation of effector cells specific for particular target anti-
gens requires in vitro stimulation of peripheral T cells with both
antigen presenting cells (APC) and a source of antigen (e.g.,
actual tumor cells, tumor lysate or protein, or a synthetic pep-
tide, mRNA, or DNA within a shuttle vector). Isolating CTL reac-
tive to a tumor-associated target antigen can be difficult if the
antigen is expressed during normal development, since most or
all of the high-avidity antigen-reactive CD8+ T cells may have
been deleted from the repertoire. To maximize the chances of
successfully activating and expanding rare reactive cells, APCs
expressing “optimal” costimulatory signals (e.g., mature dendrit-
ic cells or artificial APC) are now commonly being used. In addi-
tion, supplemental cytokines or additional signals normally
derived from APC or CD4+ T helper cells that may affect the
quality of effector cell generation are being studied (e.g., IL-7 for
naïve T cell survival and IL-15 for expansion of primed CD8+ T
cells) (Janssen et al., 2003; Lu et al., 2002; Lynch and Miller,
1994).
Ex vivo culture techniques can be used to generate antigen-
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Figure 1. Critical checkpoints and pitfalls in adoptive T cell immunotherapy
Following selection of a target antigen, T cells are stimulated in vitro, and reactive cells isolated and expanded to large numbers. After infusion into patients,
the T cells must persist, retain function, and localize to tumor sites to be effective. Failure to support in vivo survival can result in apoptosis of the transferred
cells, which interferes with efficacy. Normal tissues may also express the targeted antigen, and strategies to avoid injury to such tissues must be considered.
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specific effector cells either as components of enriched T cell
lines or as homogeneous populations of T cell clones. T cell
lines are easier to generate and can potentially include both
CD4+ and CD8+ antigen-reactive effector T cells, and the admin-
istered population of tumor-reactive cells may retain greater in
vivo proliferative potential due to having undergone fewer divi-
sions ex vivo. However, there can be unpredictable variability
among the T cell lines generated, and the heterogeneous effec-
tor populations can only be imprecisely characterized. By con-
trast, the use of homogeneous populations of CTL clones
allows for the administration of effector cells with well-defined
specificity, avidity, effector function, and magnitude, which facili-
tates analysis of the basis for therapeutic success or failure.
Clones are commonly generated by growing colonies derived
from individual CTL present in T cell lines plated in limiting dilu-
tion. Recently developed techniques for identifying and isolating
rare specifically reactive T cells from larger populations—such
as the use of peptide-MHC tetramers or a bispecific antibody to
capture T cells producing IFNγ in response to specific stimula-
tion—are greatly improving the efficiency of generating both T
cell lines and clones (Becker et al., 2001; Keenan et al., 2001).
Ex vivo effector cell expansion
Once CTL lines or clones have been generated and character-
ized, the cells must be expanded to numbers sufficient for clini-
cal use. Methods continue to be developed and improved to
provide optimal cycles of stimulation and growth in vitro by pro-
viding signals via TCR engagement, accessory molecules, and
growth factors. A standard protocol for expanding CTL clones
used in several clinical trials employs TCR stimulation to acti-
vate T cells plus allogeneic feeder cells for costimulatory sup-
port and 50 IU/ml IL-2 as a growth factor, typically yielding up to
1000-fold expansion of T cells during a two-week cycle (Riddell
and Greenberg, 1990). Alternative methods also involve provid-
ing some form of TCR stimulation and costimulatory signals via
activating antibodies presented on plastic beads or artificial
APCs (AAPCs) in the presence of IL-2 (Garlie et al., 1999). In
fact, recent studies with such AAPCs have suggested that pro-
viding antiapoptotic signals via ligation of 4-1BB on CD8+ cells
in addition to costimulatory and TCR signals may enhance cell
yield (Maus et al., 2002). Alternatively, TILs have been expand-
ed by culturing in >100× higher levels of IL-2 (Dudley et al.,
2002b), which yields large cell numbers and can bypass the
requirement for TCR stimulation but may result in abnormal cell
function and survival.
IL-2, the canonical T cell growth factor, promotes the cell
cycle progression of previously activated and cycling T cells;
however, it also predisposes the cycling cells to activation-
induced cell death (AICD) if the TCR is engaged, presumably as
a form of negative feedback control of expanding T cells (Zheng
et al., 1998). IL-15, which signals through the same β and γ
receptor chains as IL-2, may rescue cells from AICD. Recent
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Figure 2. Potential genetic modifications of T cells to enhance adoptive immunotherapy
Specificity: T cells can acquire the desired specificity and affinity for the selected target antigen by introduction of either defined TCR chains or chimeric
antigen receptors with antigen binding domains fused to intracellular signaling domains. 
Survival: Regulated growth/survival signals delivered following target recognition can be provided by restoring costimulatory signals via CD28 or introducing
chimeric cytokine receptors that can be triggered by cytokines produced by T cell activation. 
Localization: For tumor eradication, T cells can be directed to tumors in tissues by expression of tissue-specific chemokine receptors such as CXCR4. 
Effector function: Intracellular signals such as those mediated via Cbl-b that normally inhibit T cell activation signals may be blocked to sustain effector func-
tions, including cytokine production and cytolysis, promoting effective antitumor responses.
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studies by our group (unpublished data) and others have sug-
gested that IL-15 may better promote expansion and survival of
CTL (Brentjens et al., 2003; Lu et al., 2002). This improved sur-
vival with IL-15 may be due to intracellular signaling properties
of the unique α chain of the IL-15 receptor (IL-15Rα) not provid-
ed by the nonsignaling IL-2Rα chain (Bulfone-Pau et al., 1999),
or to IL-2 and IL-15 delivering qualitatively or quantitatively dif-
ferent signals through the shared signal-transducing β and γ
chains as a consequence of the kinetics or duration of the sig-
nals. For example, signaling by IL-15 but not IL-2 may upregu-
late the antiapoptotic protein Bcl-xL (Brentjens et al., 2003).
Enhancement of in vivo survival of effector T cells
Transferred T cells must persist in vivo to mediate therapeutic
efficacy. Clinical trials with CD8+ CTL clones have demonstrated
persistence of infused T cells for prolonged periods if in vivo
antigen burden is low, but rapid disappearance of CTL if signifi-
cant levels of antigen are present (Walter et al., 1995;Yee et al.,
2002). Both cotransfer of CD4+ T cell help and administration of
IL-2 in vivo have been shown to prolong the survival of CTL
(Blattman et al., 2003; Yee et al., 2002). Similar to strategies
being pursued to optimize in vitro T cell expansion and survival,
providing additional signals in vivo via costimulatory molecules
such as 4-1BB or CD28 or via cytokines such as IL-7, IL-15, and
IL-21 may prove useful for prolonging the in vivo survival and
therapeutic efficacy of transferred T cells (Lu et al., 2002; Lynch
and Miller, 1994). However, in vivo regimens will need to be
defined that are both effective and avoid significant toxicity.
An alternative strategy to enhance CTL survival in vivo may
be to transfer T cells into lymphopenic hosts, which takes
advantage of the natural host homeostatic response to promote
expansion of the remaining T cells. Prior lymphodepletion has
improved the persistence and therapeutic efficacy of transferred
CD8+ cells in murine models of adoptive therapy (Dummer et
al., 2002) and has appeared promising during treatment of
patients with advanced metastatic melanoma (Dudley et al.,
2002a). However, the magnitude and duration of lymphodeple-
tion and short- and long-term safety profiles of this approach
still require evaluation.
Building a better T cell
While modifying costimulatory signals or cytokines provided
either in vitro or in vivo may result in greater numbers of effector
cells that survive longer after infusion, it may also be desirable
to alter specific characteristics of the cells generated in order to
improve their efficacy. Advances in genetic engineering, in con-
cert with a greater understanding of the immune response at a
molecular level, have fostered efforts to genetically modify
effector cells to provide desired antigen specificity, and
enhanced effector cell survival, localization, function, and safe-
ty (Figure 2).
Specificity
One obstacle to broadly pursuing T cell transfer as a therapeutic
modality is the requirement to generate sufficiently high-avidity
tumor-reactive CTL de novo for every patient. This problem
could be solved if an autologous T cell found to be effective and
safe in one patient could be stored and used in other patients
with tumors expressing the same antigen. Although major and
minor histocompatibility disparities between individuals make
this impossible, molecular technologies have now made it pos-
sible to clone and then express the TCR chains as a means to
engineer autologous effector T cells with the desired specifici-
ty/avidity. Thus, a library of effective TCR α and β chain pairs
could be cloned into retroviral vectors, and the appropriate TCR
expressed in T cells of patients with tumors expressing the
same antigen and HLA-restricting allele (Clay et al., 1999;
Cooper et al., 2000; Stanislawski et al., 2001).
This approach can also be adapted to produce TCRs with
high affinity for targets even if T cells with such receptors have
been deleted or tolerized. T cells with low affinity can readily be
generated, and the TCR chains can then be cloned, mutage-
nized in vitro, displayed on the surface of yeast (Holler et al.,
2000) or on retrovirally transduced T cells (Kessels et al., 2000),
and selected for the desired increase in affinity via a high-
throughput screening technology such as binding to peptide-
MHC tetramers. Another strategy for identifying high-affinity
TCRs is screening for T cells that can recognize allogeneic pep-
tide/MHC complexes, since such T cells have not been subject-
ed to negative selection during development. For example,
HLA-A2+ stimulator cells pulsed with peptides can be used to
generate alloreactive CD8+ clones from HLA-A2-negative indi-
viduals that are then screened to isolate the CTLs that recog-
nize the A2 alloantigen only if it contains the specific peptide,
and these CTLs used as TCR donors (Stanislawski et al.,
2001). Alternatively, xenogeneic TCRs can be isolated by stimu-
lating mice transgenic for the human HLA-A2 molecule with
human tumor proteins (Stanislawski et al., 2001). An additional
method of providing effector cells with high-affinity receptors
requires generating monoclonal antibodies to target cells and
screening for specificity for peptide/MHC complexes. This
approach takes advantage of the fact that antibodies have high-
er affinities than TCRs, and that the antibody repertoire has not
been tolerized against TCR epitopes. Such “MHC-restricted”
antibodies can be engineered to behave as TCRs by construct-
ing chimeric antigen receptors (CARs) composed of the antigen
binding domain of the antibody as the extracellular portion
fused with an intracellular activation domain, thus linking anti-
gen recognition with T cell activation (Chames et al., 2002).
However, high-affinity receptors generated by any of these
approaches will have to be carefully evaluated for the potential
to induce autoimmunity by recognition of the target antigen at
low levels on normal tissues or by crossreactivity with other self-
antigens (Holler et al., 2003).
Tumors may evade even effector cells with high-affinity
receptors for obligate oncoproteins by disrupting the antigen
processing or presentation machinery. Thus, CARs that recog-
nize intact membrane proteins are also being designed to rec-
ognize tumor antigens independent of antigen processing or
MHC expression. Such CARs consist of an extracellular domain
(e.g., either a ligand for a membrane molecule or a single chain
antibody) that can bind a membrane antigen on the tumor cell,
fused to a cytoplasmic signaling domain such as the TCR ζ
chain (Eshhar et al., 1993; Roberts et al., 1994). A large number
of different “tumor-associated” antigens including CEA, PSMA,
and CD19 have already been successfully targeted experimen-
tally using CARs (Brentjens et al., 2003; Sadelain et al., 2003).
One potential drawback of this approach is that since CARs nei-
ther promote assembly of the complete TCR signaling complex
nor mimic the classical on/off kinetics of TCR-peptide-MHC
interactions (Kalergis et al., 2001), the atypical strength and
duration of activation signals could result in T cell
anergy/exhaustion or apoptosis. At this point there are no clear
rules of engagement regarding the ideal CAR affinity or costim-
ulatory requirements for in vivo efficacy, and this may need to
P R I M E R
CANCER CELL : MAY 2003 435
be determined for each CAR generated.
In vivo survival
T cells can also be modified to express autocrine growth factors
including IL-2 or IL-15 to sustain survival following transfer.
However, cytokine expression not coordinately regulated with
antigen stimulation could result in T cell dysfunction or apopto-
sis as well as cytokine-mediated toxicity. Signaling through the
costimulatory molecule CD28 concurrent with T cell recognition
of antigen would synchronize endogenous production of IL-2
with TCR signals. Although differentiation of CD8+ cells to effec-
tor cells is generally associated with loss of CD28 expression
(Appay et al., 2002), recent studies from our group have shown
that reexpression of CD28 in human effector CD8 T cells, via a
retroviral vector, results in the restoration of regulated IL-2 pro-
duction (unpublished data). Unfortunately, tumors rarely
express CD80 or CD86, the ligands for CD28, rendering this
approach ineffective in a majority of cases. One solution to this
problem would be to attach intracellular signaling domains from
CD28 to the signaling TCR ζ domains of CARs, which can then
provide both TCR and costimulation signals (Sadelain et al.,
2003). Alternatively, chimeric cytokine receptors (CCRs) may
be used to synchronize antigen stimulation and cytokine sig-
nals. One such CCR employs the extracellular domain of the
GM-CSF receptor fused to the intracellular signaling domains of
the IL-2 receptor and utilizes the normal production of GM-CSF
following antigen recognition by effector CD8+ T cells as a regu-
lated autocrine growth factor. This chimeric receptor has been
shown to deliver IL-2 prosurvival signals to T cells and enhance
T cell proliferation in tumor-bearing mice (Cheng et al., 2002).
Thus, delivery of prosurvival proliferation signals to T cells
linked to target recognition in vivo may provide a means to
improve therapeutic efficacy.
Localization
Effective immunotherapy also requires localization of trans-
ferred CTL to tumor sites. Direct injection of CTL into tumors
has met with limited success and would only be applicable to
accessible, localized tumor masses. For other tumor sites, pref-
erential migration/homing of transferred T cells by enhancing
the expression of adhesion molecules or chemokine receptors
may be a more viable strategy. For example, introduction of the
chemokine receptor CXCR4 into T cells may be useful to target
CTL to bone marrow for the treatment of leukemias or metasta-
tic tumors growing in the milieu of marrow stromal cells which
produce SDF-1, the ligand for CXCR4 (Peled et al., 1999).
Similarly, introduction of CXCR5 or CXCR2 to T cells might be
used for targeting CTL to follicular lymphoma cells which pro-
duce CXCL13 or melanoma cells which produce CXCL1,
respectively (Husson et al., 2002; Kershaw et al., 2002). As our
insights into the mechanisms of tissue-specific homing
increase, directing the migration of effector T cells to desired
sites should become an increasingly important aspect of thera-
py design.
Effector function
During prolonged antigen stimulation with large tumor burdens,
CD8+ T cells may become functionally impaired (manifested by
decreased cytokine production and lytic activity) and subse-
quently deleted. Thus, methods to enhance the in vivo function
of transferred CTL may be required for effective therapy. The
surface receptor NKG2D has been shown to deliver potent acti-
vation and costimulatory signals to T cells (Bauer et al., 1999),
and overexpression of NKG2D in CTL might provide a means to
augment TCR signal strength following target recognition.
Importantly, the ligands for NKG2D, MICA and MICB, are
stress-induced and often expressed on tumor cells (Groh et al.,
1999). Alternatively, targeted decreases in negative intracellular
signals, by retroviral transfer of small inhibitory RNA (siRNA) to
decrease endogenous mRNA levels or expression of dominant-
negative versions of suppressive proteins, may be useful to
enhance CTL function. The list of candidate inhibitory protein
targets is long, including cell-surface proteins (CTLA-4, PD-1),
cell cycle regulators (p27kip), kinase phosphatases (SHP-1),
and adaptor proteins (SOCS- & Cbl-family members). Our lab
has pursued decreasing levels of Cbl-b, an E3-ubiquitin ligase,
in T cells. Consistent with studies in Cbl-b−/− mice (Chiang et al.,
2000), downregulation of Cbl-b in immortalized T cell lines and
in human T cells results in a decreased threshold for TCR sig-
naling and in the ability to produce IL-2 and proliferate in
response to antigen alone, effectively bypassing the require-
ments for CD28 costimulation during T cell activation (unpub-
lished data). Depending on the requirements for effective
therapy in specific settings, it may be possible to “tailor” levels of
selected intracellular proteins and thus direct different effector
functions for maximum therapeutic efficacy.
Safety
Various techniques are being developed to allow the selective
elimination of infused cells in the event of undesirable toxicity.
The primary potential toxicity associated with adoptive T cell
immunotherapy is injury of normal tissues also expressing the
targeted antigen. Autoimmunity may be expected but tolerable,
as when melanoma-specific CTL cause vitiligo (Yee et al.,
2000), or potentially dangerous, as might occur if the adminis-
tration of T cells expressing CD19-specific CARs led to B cell
aplasia (Brentjens et al., 2003). Alternatively, autoimmunity
against other (nontargeted) self-antigens could result from the
use of T cell lines rather than clones in therapy, particularly if in
vitro strategies are used that overcome tolerance and expand
rare endogenous autoreactive CTL. Finally, there is also a
potential risk of autoimmunity with T cells expressing introduced
TCR chains, as alternative pairing of endogenous and trans-
duced TCR α and β chains could yield an autoreactive receptor.
An additional risk associated with the genetic modification
of effector cells is the possibility of oncogenesis. As demonstrat-
ed recently (Marshall, 2003), the introduction of recombinant
genes into cells can lead to leukemias in human patients due to
the unintentional activation of oncogenes. Using homogeneous
populations of transduced CTL clones rather than lines has the
advantage of allowing for efficient screening for a potentially
oncogenic integration event prior to infusion. However, the risk
of toxicity or safety may not always be easy to define, and safe-
ty features may need to be incorporated into the engineering of
effector cells.
Introducing a conditional “suicide gene” into effector T cells
is the most common method used to confer the ability to selec-
tively eliminate the transferred cells should toxicities occur.
Initially, genes derived from pathogens such as the HSV thymi-
dine kinase (TK) gene were utilized, since cells expressing this
protein convert the antiviral drug ganciclovir into a lethal product
(Springer and Niculescu-Duvaz, 2000). Limitations with this
strategy became apparent in clinical trials, however, as it was
discovered that not only were slowly dividing transferred T cells
expressing TK not efficiently eliminated, but that host CD8+ T
cell responses to the viral protein led to selective and often rapid
elimination of the transferred T cells (Riddell et al., 1996;
Verzeletti et al., 1998). Therefore, recent endeavors have
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focused on inducible suicide genes derived from the endoge-
nous apoptosis pathway. One such approach consists of a
chimeric molecule engineered to induce cell death via the Fas
pathway after the binding of an otherwise nontoxic drug that
causes multimerization (Thomis et al., 2001). As the chimeric
molecule is derived from human proteins instead of a pathogen,
chances of inducing an immune response are minimal. In addi-
tion, induction of cell death is not dependent upon active cell
cycling. Alternative “safety switches” include other inducible
death signals such as multimerizable caspases or a tetracy-
cline-inducible toxin.
Concluding remarks
T cell therapy has already shown promise in treating several
diseases, including CMV, EBV, melanoma, and leukemia
(Dudley et al., 2002a; Rooney et al., 1998; Walter et al., 1995;
Warren et al., 1998; Yee et al., 2002). In vitro technologies are
making it increasingly possible to identify tumor antigens and to
isolate and expand T cells reactive with such proteins. In addi-
tion, the availability of recombinant cytokines and reagents to
trigger costimulatory molecules are providing means to promote
the in vivo survival and function of transferred cells. Finally,
advances in molecular immunology and genetic engineering
are allowing the introduction of an increasing number of novel
genes into T cells that can alter and/or enhance effector cell sur-
vival, localization, function, and safety. With the current pace of
progress, reliable methods for engineering an effective immune
response against cancer should soon become a clinical reality.
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